CN114072399A - 芳甲酰胺类化合物及其制备方法和医药用途 - Google Patents

芳甲酰胺类化合物及其制备方法和医药用途 Download PDF

Info

Publication number
CN114072399A
CN114072399A CN202180004411.6A CN202180004411A CN114072399A CN 114072399 A CN114072399 A CN 114072399A CN 202180004411 A CN202180004411 A CN 202180004411A CN 114072399 A CN114072399 A CN 114072399A
Authority
CN
China
Prior art keywords
alkyl
cycloalkyl
compound
alkoxy
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180004411.6A
Other languages
English (en)
Inventor
殷惠军
闫旭
宗利斌
刘国标
张守良
陈彬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institutes of Pharmaceutical R&D Co Ltd
Original Assignee
National Institutes of Pharmaceutical R&D Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institutes of Pharmaceutical R&D Co Ltd filed Critical National Institutes of Pharmaceutical R&D Co Ltd
Publication of CN114072399A publication Critical patent/CN114072399A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

本发明涉及芳甲酰胺类化合物及其制备方法和医药用途。特别地，本发明涉及通式(I)所示的化合物、其制备方法及含有该化合物的药物组合物，及其作为P2X3受体拮抗剂的用途，该化合物及含有该化合物的药物组合物可以用于治疗和/或预防与P2X3活性相关的疾病，例如慢性咳嗽、疼痛、子宫内膜异位、膀胱过度活动症等。其中通式(I)中的各取代基的定义与说明书中的定义相同。

Description

PCT国内申请，说明书已公开。

Claims (19)

  1. PCT国内申请，权利要求书已公开。
CN202180004411.6A 2020-05-25 2021-05-24 芳甲酰胺类化合物及其制备方法和医药用途 Pending CN114072399A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020104471930 2020-05-25
CN202010447193 2020-05-25
PCT/CN2021/095424 WO2021238834A1 (zh) 2020-05-25 2021-05-24 芳甲酰胺类化合物及其制备方法和医药用途

Publications (1)

Publication Number Publication Date
CN114072399A true CN114072399A (zh) 2022-02-18

Family

ID=78745622

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180004411.6A Pending CN114072399A (zh) 2020-05-25 2021-05-24 芳甲酰胺类化合物及其制备方法和医药用途

Country Status (4)

Country Link
CN (1) CN114072399A (zh)
AU (1) AU2021282039A1 (zh)
TW (1) TW202144342A (zh)
WO (1) WO2021238834A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022199654A1 (en) * 2021-03-24 2022-09-29 Chengdu Anticancer Bioscience, Ltd. Heteroaryl-heteroaryl-o-phenyl compounds, compositions and methods of treating cancer disorders

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11349572A (ja) * 1998-04-07 1999-12-21 Fujisawa Pharmaceut Co Ltd 新規アミド誘導体およびその塩
WO2009058298A1 (en) * 2007-10-31 2009-05-07 Merck & Co., Inc. P2x3, receptor antagonists for treatment of pain
CN101981003A (zh) * 2008-02-29 2011-02-23 雷诺维思公司 酰胺化合物、组合物及其应用
US20150080408A1 (en) * 2009-06-22 2015-03-19 Roche Palo Alto Llc Pyridinyl amides as p2x3 and p2x2/3 inhibitors
CN107207507A (zh) * 2014-12-09 2017-09-26 拜耳公司 1,3‑噻唑‑2‑基取代的苯甲酰胺
WO2019219674A1 (en) * 2018-05-15 2019-11-21 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
WO2019219672A1 (en) * 2018-05-15 2019-11-21 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
WO2020260463A1 (en) * 2019-06-27 2020-12-30 Bayer Aktiengesellschaft Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010069794A1 (en) * 2008-12-16 2010-06-24 F. Hoffmann-La Roche Ag Thiadiazole-substituted arylamides
WO2010149541A1 (en) * 2009-06-22 2010-12-29 F. Hoffmann-La Roche Ag Novel oxazolone and pyrrolidinone-substituted arylamides

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11349572A (ja) * 1998-04-07 1999-12-21 Fujisawa Pharmaceut Co Ltd 新規アミド誘導体およびその塩
WO2009058298A1 (en) * 2007-10-31 2009-05-07 Merck & Co., Inc. P2x3, receptor antagonists for treatment of pain
CN101981003A (zh) * 2008-02-29 2011-02-23 雷诺维思公司 酰胺化合物、组合物及其应用
US20150080408A1 (en) * 2009-06-22 2015-03-19 Roche Palo Alto Llc Pyridinyl amides as p2x3 and p2x2/3 inhibitors
CN107207507A (zh) * 2014-12-09 2017-09-26 拜耳公司 1,3‑噻唑‑2‑基取代的苯甲酰胺
WO2019219674A1 (en) * 2018-05-15 2019-11-21 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
WO2019219672A1 (en) * 2018-05-15 2019-11-21 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
WO2020260463A1 (en) * 2019-06-27 2020-12-30 Bayer Aktiengesellschaft Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide
CN114026086A (zh) * 2019-06-27 2022-02-08 拜耳公司 3-(5-甲基-1,3-噻唑-2-基)-n-{(1r)-1-[2-(三氟甲基)嘧啶-5-基]乙基}苯甲酰胺的类似物

Also Published As

Publication number Publication date
WO2021238834A1 (zh) 2021-12-02
AU2021282039A1 (en) 2022-12-01
TW202144342A (zh) 2021-12-01

Similar Documents

Publication Publication Date Title
JP7017521B2 (ja) アクチビン受容体様キナーゼの阻害剤
TWI718207B (zh) 苯並呋喃類衍生物、其製備方法及其在醫藥上的應用
JP6782255B2 (ja) ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法
JP7038414B2 (ja) ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
CN107759587B (zh) [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
JP5617919B2 (ja) テトラヒドロベンゾチオフェン化合物
TW202115076A (zh) 嘧啶并五員氮雜環類衍生物、其製備方法及其在醫藥上的應用
EP3766882B1 (en) Phthalazine isoxazole alkoxy derivatives, preparation method thereof, pharmaceutical composition and use thereof
CN110072865B (zh) 吡咯并芳杂环类化合物及其制备方法和医药用途
TWI599562B (zh) 作爲ｔｔｘ－ｓ阻斷劑之醯胺衍生物
CN103097340A (zh) 治疗活性组合物及其使用方法
JP6473420B2 (ja) 複素環スルホンアミド誘導体及びそれを含有する医薬
TWI577677B (zh) 作爲ｔｔｘ－ｓ阻斷劑之吡咯並吡啶酮衍生物
TW202012412A (zh) 一種含有醯胺類衍生物的醫藥組成物及其製備方法和應用
TWI596095B (zh) Dihydropyridazine-3,5-dione derivatives
CN107033097B (zh) 噁二唑类衍生物、其制备方法及其在医药上的应用
TWI701251B (zh) 吡唑并[1,5-a][1,3,5]三-2-胺類衍生物、其製備方法及其在醫藥上的應用
CN111868056A (zh) 1,2,4-噁二唑类化合物及其制备方法和医药用途
CN111320633A (zh) 吡咯/咪唑并六元杂芳环类化合物及其制备方法和医药用途
CN114072399A (zh) 芳甲酰胺类化合物及其制备方法和医药用途
TW202214603A (zh) 一種噠嗪類衍生物游離鹼晶型及其製備方法和應用
TWI601726B (zh) 吡唑並吡啶衍生物作爲ｔｔｘ－ｓ阻斷劑
TW202128693A (zh) 含吡唑多環類衍生物抑制劑、其製備方法和應用
CN114845996A (zh) 一种含苯环的化合物及其应用
WO2021027647A1 (zh) 桥杂环基取代的嘧啶类化合物及其制备方法和医药用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40061563

Country of ref document: HK